ArticleJAMA cardiology2019
Association of Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular Disease.
Article in JAMA cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 157 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
157 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Adherence to Lipid-Lowering Therapies and Cardiovascular Outcomes in Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis.Journal of the American Heart Association · 2025 · on this mapPooled it
- Methods and validity indicators for measuring adherence to statins in secondary cardiovascular prevention: a systematic review.Systematic reviews · 2025Pooled it
- Medication adherence trajectories and clinical outcomes in patients with cardiovascular disease: a systematic review and meta-analysis.Journal of global health · 2025Pooled it
- An Evidence Map of the Women Veterans' Health Literature, 2016 to 2023: A Systematic Review.JAMA network open · 2025Pooled it
- The prevention of stroke by statins: A meta-analysis.Medicine · 2022Pooled it
- Implementation strategies to improve statin utilization in individuals with hypercholesterolemia: a systematic review and meta-analysis.Implementation science : IS · 2021Pooled it
- Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease.Journal of the American Heart Association · 2024Trial
- Adherence with protocol medication use and mortality from unrelated causes in a prevention trial.Preventive medicine · 2021Trial
- Effects of a pharmaceutical care intervention on clinical outcomes and patient adherence in coronary heart disease: the MIMeRiC randomized controlled trial.BMC cardiovascular disorders · 2021Trial
- A controlled trial of dissemination and implementation of a cardiovascular risk reduction strategy in small primary care practices.Health services research · 2020Trial
- Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis.European heart journal · 2020Trial
- Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial.JAMA cardiology · 2019Trial
- Statin adherence among patients with hypertension in Swedish primary health care: a QregPV cohort study using explainable machine learning.European heart journal. Cardiovascular pharmacotherapy · 2026Article
- Treatment Patterns and Healthcare-Related Costs in Patients with Atherosclerotic Cardiovascular Disease: Insights from a Large US Healthcare Insurer.Drugs - real world outcomes · 2026Article
- Fenofibrate discontinuation and the association with clinical outcomes in primary biliary cholangitis patients receiving combination therapy.International journal of clinical pharmacy · 2026Article
- Predictors of Medication Adherence Among Taiwanese Community-Based Adults with Hypertension: The Application of Temporal Self-Regulation Theory.Behavioral sciences (Basel, Switzerland) · 2026Article
- Lipid-Lowering Treatment in Familial Hypercholesterolaemia, 1996-2021: A Nationwide Study.The Lancet regional health. Europe · 2026Article
- Low-density lipoprotein cholesterol longitudinal trajectories and clinical outcomes following an acute coronary syndrome.American journal of preventive cardiology · 2026Article
- Pharmacogenetic Associations with Statin Regimen Modification, Intolerance, and Adverse Outcomes in Coronary Artery Disease Patients.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Statin Eligibility Disparities with Transition from the Pooled Cohort Equations to the AHA PREVENT.medRxiv : the preprint server for health sciences · 2026Article
97 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
6 authors.
Funding
Abstract
Importance: Statins decrease mortality in those with atherosclerotic cardiovascular disease (ASCVD), but statin adherence remains suboptimal. Objective: To determine the association between statin adherence and mortality in patients with ASCVD who have stable statin prescriptions. Design, Setting, and Participants: This retrospective cohort analysis included patients who were between ages 21 and 85 years and had 1 or more International Classification of Diseases, Ninth Revision, Clinical Modification codes for ASCVD on 2 or more dates in the previous 2 years without intensity changes to their statin prescription who were treated within the Veterans Affairs Health System between January 1, 2013, and April 2014. Exposures: Statin adherence was defined by the medication possession ratio (MPR). Adherence levels were categorized as an MPR of less than 50%, 50% to 69%, 70% to 89%, and 90% or greater. For dichotomous analyses, adherence was defined as an MPR of 80% or greater. Main Outcomes and Measures: The primary outcome was death of all causes adjusted for demographic and clinical characteristics, as well as adherence to other cardiac medications. Results: Of 347 104 eligible adults with ASCVD who had stable statin prescriptions, 5472 (1.6%) were women, 284 150 (81.9%) were white, 36 208 (10.4%) were African American, 16 323 (4.7%) were Hispanic, 4093 (1.2%) were Pacific Islander, 1293 (0.4%) were Native American, 1145 (0.3%) were Asian, and 1794 (0.5%) were other races. Patients taking moderate-intensity statin therapy were more adherent than patients taking high-intensity statin therapy (odds ratio [OR], 1.18; 95% CI, 1.16-1.20). Women were less adherent (OR, 0.89; 95% CI, 0.84-0.94), as were minority groups. Younger and older patients were less likely to be adherent compared with adults aged 65 to 74 years. During a mean (SD) of 2.9 (0.8) years of follow-up, there were 85 930 deaths (24.8%). Compared with the most adherent patients (MPR ≥ 90%), patients with an MPR of less than 50% had a hazard ratio (HR; adjusted for clinical characteristics and adherence to other cardiac medications) of 1.30 (95% CI, 1.27-1.34), those with an MPR of 50% to 69% had an HR of 1.21 (95% CI, 1.18-1.24), and those with an MPR of 70% to 89% had an HR of 1.08 (95% CI, 1.06-1.09). Conclusions and Relevance: Using a national sample of Veterans Affairs patients with ASCVD, we found that a low adherence to statin therapy was associated with a greater risk of dying. Women, minorities, younger adults, and older adults were less likely to adhere to statins. Our findings underscore the importance of finding methods to improve adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.